Kamada will supply its KamRab product for treating rabies.
Kamada Ltd. (TASE:KMDA), which develops therapeutics based on human plasma, has won a Mexican tender for the supply of a rabies treatment. Kamada will supply its KamRab product. Several companies participated in the tender. Kamada won the bulk of the tender, alongside a number of other companies. Kamada’s contract with Mexico’s Ministry of Health will be worth $2 million in 2006 alone, and the contract may be extended and expanded.
Kamada has marketed KamRab, a generic treatment for rabies, in South American and Asian countries since 2003. KamRab is now undergoing approval procedures in the US and other countries.
Kamada said KamRab sales would total $3 million in 2005.
Published by Globes [online], Israel business news - www.globes.co.il - on December 28, 2005